Last reviewed · How we verify

NCT03630029

RBT-1 Phase 1b Clinical Trial in Healthy Volunteers and Subjects With CKD

Withdrawn Phase 1 Last updated 11 May 2020
What this trial tests

Phase 1 trial testing FeS and SnPP in Acute Kidney Injury. Withdrawn.

Timeline
15 September 2018
Primary endpoint
30 November 2018
31 March 2019

Quick facts

Lead sponsorRenibus Therapeutics, Inc.
PhasePhase 1
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationnon randomized
Designsequential
Maskingnone
Primary purposeprevention
Start date15 September 2018
Primary completion30 November 2018
Estimated completion31 March 2019

Drugs / interventions tested

Conditions studied

Sponsor

Renibus Therapeutics, Inc. — full company profile →

Who can join

Adults 18 to 80, any sex, with Acute Kidney Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Phase 1b study to evaluate the safety, tolerability and pharmacodynamic effect of RBT-1 in healthy volunteers and subjects with stage 3b-4 CKD.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Acute Kidney Injury

Currently open trials in the same condition.

Other Renibus Therapeutics, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03630029.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing